Invidia partners with Amdipharm to bring products to Asian markets

Singapore-based biopharmaceuticals firm Invida Group Pte has entered into an agreement with UK-headquartered Amdipharm for the licensing and commercialization of its proprietary products throughout Asia.

Under this agreement, Invida will leverage its full suite of capabilities to bring Amdipharm's products to market, from regulatory approval and licensing, through packaging and supply chain optimization, to commercialization, sales, and marketing.

Amdipharm specializes in acquiring products from leading pharmaceutical companies that serve essential medical needs. These products, which come from leading pharmaceutical companies including Abbott, Roche and Novartis, are used to treat a variety of critical medical conditions, including Parkinson's disease, migraines, hypertension and bacterial infections.